[Form 4] Genpact LTD Insider Trading Activity

Rhea-AI Filing Summary

Insider transactions by Genpact Ltd (G): Senior Vice President and CHRO Piyush Mehta executed multiple transactions on 09/12/2025. He acquired 50,000 common shares at $31.50, and sold 50,000 shares and 26,902 shares at weighted-average prices of $42.58 (sales ranged from $42.42 to $42.73 and $42.42 to $42.70 respectively). After these transactions he beneficially owns 134,880 common shares. The filing notes he holds 10,222 shares under the ESPP (including 284 shares acquired since his prior Form 4). The Form 4 was signed by an attorney-in-fact on 09/15/2025.

Positive

• Realized gain potential: Exercised 50,000 shares at $31.50 and sold shares at a weighted-average of $42.58, indicating a per-share spread of about $11.08 on shares sold.
• Continued ownership: Reporting person retains 134,880 shares after transactions, maintaining significant ongoing ownership.
• ESPP participation: Holds 10,222 shares under the Genpact ESPP, including 284 shares acquired since prior Form 4.

Negative

• Net reduction in holdings: Total common shares beneficially owned decreased from 211,782 to 134,880 following sales of 76,902 shares.
• Insider sales disclosed: Two sales on 09/12/2025 (50,000 and 26,902 shares) may be viewed by some investors as liquidity-driven reducing insider share count.

Insights

Financial Analyst

TL;DR: Insider exercised equity at $31.50 then sold portions at ~42.58, realizing gains; overall holdings decreased to 134,880 shares.

The transactions show a typical option exercise followed by partial disposition to monetize gains. Acquisition of 50,000 shares at $31.50 and immediate sales at a weighted-average of $42.58 imply a realized pre-tax spread of roughly $11.08 per share on those sold, though exact realized gain depends on which specific shares were sold. The reporting person still retains a meaningful stake (134,880 shares) and continues participation in the ESPP (10,222 shares), indicating retained exposure while capturing liquidity.

Corporate Governance Expert

TL;DR: Transactions were disclosed in compliance with Section 16; no regulatory or governance concerns evident from the filing.

The Form 4 provides required detail including transaction codes, weighted-average sale price ranges, ESPP holdings, and a signed filing. The record includes an attorney-in-fact signature and explanations for price ranges and vesting history of the option. There are no disclosed exceptions, amendments, or unusual arrangements in the filing text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehta Piyush

(Last) (First) (Middle)

C/O GENPACT LLC

521 FIFTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NY 10175

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Genpact LTD [ G ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President and CHRO

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/12/2025		M		50,000	A	$31.5	211,782(1)	D
Common Shares	09/12/2025		S		50,000	D	$42.58(2)	161,782	D
Common Shares	09/12/2025		S		26,902	D	$42.58(3)	134,880	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$31.5	09/12/2025		M			50,000	(4)	04/01/2028	Common Shares	50,000	$0	0	D

Explanation of Responses:

1. Includes 284 shares acquired under the Genpact Employee Stock Purchase Plan ("ESPP") since the reporting person's Form 4 filed on March 13, 2025. The reporting person currently holds a total of 10,222 shares under the ESPP.

2. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $42.42 to $42.73. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $42.42 to $42.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. The option vested 50% on April 2, 2021 and the remainder on April 2, 2023.

Remarks:

	/s/ Thomas D. Scholtes, as Attorney-in-fact for Piyush Mehta	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Piyush Mehta report for Genpact (G)?

He acquired 50,000 common shares at $31.50 and sold 50,000 and 26,902 shares at weighted-average sale prices of $42.58 on 09/12/2025.

How many Genpact shares does Piyush Mehta beneficially own after the Form 4?

134,880 common shares are reported as beneficially owned following the transactions.

How many shares does Piyush Mehta hold in the ESPP?

The filing states he holds 10,222 shares under the Genpact Employee Stock Purchase Plan, including 284 shares acquired since his prior Form 4.

When was the Form 4 signed and who signed it?

The Form 4 disclosure bears the signature of Thomas D. Scholtes, as Attorney-in-fact for Piyush Mehta dated 09/15/2025.

What is the vesting history noted for the option related to these transactions?

The filing explains the related option vested 50% on April 2, 2021 and the remainder on April 2, 2023.